Intravenous Metoprolol in Septic Shock

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-01

Study Completion Date

2024-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A RCT designed to assess the effect of giving intravenous beta-blockers in patients with septic shock after achieving hemodynamic stability. The principle of this study is to control heart rate allowing for better diastolic filling and thus better perfusion.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Ivabradine on Microcirculation and Cardiac Output in Septic Shock Patients

NCT05141071

Septic Shock

COMPLETED PHASE2

Effects of Heart Control at Different Stages in Patients of Septic Shock With Tachycardia

NCT05389176

Septic Shock Tachycardia

UNKNOWN NA

Effect of Heart Rate Control With Ivabradine on Hemodynamic in Patients With Sepsis

NCT05882708

Sepsis Ivabradine Hemodynamics +1 more

RECRUITING PHASE4

Comparison of Landiolol Versus Standard of Care for Prevention of Mortality in Patients Hospitalized for a Septic Shock With Hypercontractility

NCT04748796

Septic Shock Tachycardia Mortality During Septic Shock +1 more

RECRUITING PHASE3

Protocol-driven Hemodynamic Support for Patients With Septic Shock

NCT00335907

Shock, Septic Severe Sepsis Sepsis

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A RCT, conducted at alexandria main university hospital, patients were divided into 2 groups, Control group which received the standard care for septic shock and metoprolol group which recieved intravenous metoprolol then patients were assessed for Blood pressure, heart rate, iv fluids needed, vasopressor doses and 28 days mortality

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Septic Shock Ventilator Acquired Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metoprolol group

The group that received intravenous metoprolol

Group Type ACTIVE_COMPARATOR

Intravenous metoprolol tartrate

Intervention Type DRUG

An intravenous beta-blockers, recieved FDA approval

Control group

The group that received standard care

Group Type PLACEBO_COMPARATOR

Standard Care (in control arm)

Intervention Type OTHER

Standard care according to surviving sepsis campaign

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravenous metoprolol tartrate

An intravenous beta-blockers, recieved FDA approval

Intervention Type DRUG

Standard Care (in control arm)

Standard care according to surviving sepsis campaign

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The study population included adult patients (≥ 18 years) diagnosed with septic shock secondary to VAP with sinus tachycardia, from April 1, 2022, to April 31, 2023. Septic shock was defined according to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). VAP was identified as per the guidelines provided by the American Thoracic Society and Infectious Diseases Society of America.

Exclusion Criteria

* Patients were excluded if they had contraindications to beta-blockers, had a history of heart failure, or had been receiving beta-blockers prior to the septic shock. Patients were also excluded if they developed complications from beta- blockers administration.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No